Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 2 Diabetes: full-pipeline trial registry
120 of 328 indexed Type 2 Diabetes trials are currently recruiting.
Corpus placement: #22 of 28,707 conditions by registered trial count.
328 US clinical trials · 120 currently recruiting · #22 of 28,707 conditions by registered trial count
Type 2 Diabetes: 328 US clinical trials tracked, 120 recruiting.
Type 2 Diabetes is the subject of 328 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 60 are in Phase 3-4 (later-stage) and 50 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 20 of these trials.
Enrollment posture brief
Registry condition type-2-diabetes
OPEN 120 | RECR 37% | LATE 60 | EARLY 50 | RANK #22 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Advanced Cancer (37% recruiting · 123 trials)
Type 2 Diabetes lists 120 open slots (37% of 328 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Type 2 Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Type 2 Diabetes recruits in line with its size-band peers.
120 of 328 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 2 Diabetes trials is spread across many organizations.
Eli Lilly and Company accounts for 20 of 328 trials (6.1%). 153 distinct sponsors appear on at least one study for this condition label.
-
Typical Type 2 Diabetes enrolment sits around 96 participants.
Median target enrolment is 96 among the 328 trials that report a genuine target (sentinel values excluded). 166 of those (50.6%) plan for fewer than 100 participants.
-
Type 2 Diabetes research is mostly interventional.
290 interventional and 38 observational studies make up this index (88.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
328 total, page 3 of 7
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
Stanford University
NCT06836479
SGLTi, Hepatic Glucose Production and Ketogenesis
The University of Texas Health Science Center at San Antonio
NCT05960656
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
University of Michigan
NCT06337812
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
The University of Texas Health Science Center at San Antonio
NCT05057806
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
The University of Texas Health Science Center at San Antonio
NCT07053306
Glycemic Excursion Minimization (GEM) to Outshine Health Disparities
Catherine Davis
NCT06236581
Heat Therapy in Type 2 Diabetes
Purdue University
NCT06596967
SGLT2i, Hepatic Glucose Production, and SNS
The University of Texas Health Science Center at San Antonio
NCT07053293
Mechanism of SGLT2 Inhibition in the Kidney
University of Michigan
NCT06291155
Enhancing Diabetes Care: Exposome &Amp; Sensors
University of Illinois at Chicago
NCT06989008
Precision Dosing of Metformin in Youth With T2D
University of California, San Francisco
NCT06120881
Circadian Intervention to Improve Cardiometabolic Health
University of Utah
NCT05943626
Pharmacist-led Continuous Glucose Monitoring
University of South Florida
NCT06572306
Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment
The University of Texas Medical Branch, Galveston
NCT07416799
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Adrian Vella
NCT05499702
Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access
Yale University
NCT06658067
Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes
AdventHealth Translational Research Institute
NCT04754581
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
AdventHealth Translational Research Institute
NCT06993454
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
The University of Texas Health Science Center at San Antonio
NCT06108076
Brown Adipose Tissue Activation by Spinal Cord Stimulation
Oregon Health and Science University
NCT04326192
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital
NCT05220917
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Brigham and Women's Hospital
NCT06779929
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Brigham and Women's Hospital
NCT07417618
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
Brigham and Women's Hospital
NCT07417631
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Brigham and Women's Hospital
NCT06980623
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Brigham and Women's Hospital
NCT07390110
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company
NCT05803421
SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy
Kaiser Permanente
NCT01967030
The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older
University of Illinois at Chicago
NCT05654142
Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS
Massachusetts General Hospital
NCT02087826
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
NCT06221969
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company
NCT05929079
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Eli Lilly and Company
NCT05433584
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT07033585
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1
State University of New York at Buffalo
NCT04203173
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Eli Lilly and Company
NCT06037252
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S
NCT07220759
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company
NCT06297603
Innovative Automated Insulin Delivery System for Type 2 Diabetes
Deka Research and Development
NCT06853990
Lowering the Impact of Food Insecurity in African American Adults With Type 2 Diabetes Mellitus (LIFT-DM)
State University of New York at Buffalo
NCT04181424
Personalized Dietary Management in Type 2 Diabetes
NYU Langone Health
NCT05046886
Diabetes Medical Nutrition Therapy in Southeastern African American Women
Meharry Medical College
NCT04971889
Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans
University of Texas at Austin
NCT04282395
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Zealand Pharma
NCT06926842
Together Overcoming Diabetes
Johns Hopkins Bloomberg School of Public Health
NCT04734015
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
Dana-Farber Cancer Institute
NCT04717050
The Hope App Study
See Yourself Health
NCT05729516
Randomized Controlled Trial of Digital Twin Precision Treatment: A Novel Whole Body Digital Twin Enabled Precision Treatment for Type 2 Diabetes
The Cleveland Clinic
NCT05181449
E3 Diabetes - Closing the Gap in Diabetes Control
Rush University Medical Center
NCT06643936
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
NCT05536804
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 25 |
| Phase 3 | 35 |
| Phase 4 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Type 2 Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Type 2 Diabetes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Type 2 Diabetes page
328 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Type 2 Diabetes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Type 2 Diabetes trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 2 Diabetes condition card totals 328 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.